News Detail
New Delhi, 23 April 2024: Indian pharma companies need to explore various pricing strategies to ensure optimum returns while coming up with generic drugs to utilise the patent cliff opportunities where over 20 drugs with sales worth $251 billion are going off-patent in the curren......
View Details
Source : Pharmabiz
Indian pharma
optimum
generic drugs
patent cliff
Department of Pharmaceuticals
DoP
Indian generic pharmaceutical
Biovantis Healthcare
biosimilar
Lipitor
cholesterol
Related News
- 1,200 litres Banned cough syrup concealed under garlic and onions sacks, recovered (03-04-2025)
- Dissolution Test is Minor Defect, when Active Content is Within Limit, does not Warrant Prosecution: Rajasthan HC (03-04-2025)
- Tripura DCA finds no proof of selling substandard injection by Elder Prroject and Elder Pharmaceuticals (03-04-2025)
- AP government’s crackdown on sale of banned drugs intensifies (03-04-2025)
- Fake pharmacy registration racket busted in Delhi, Council ex-registrar among 47 held (03-04-2025)
- RGHS scam: FIR against 3 in Bharatpur; loss to government exchequer due to high-value transactions (02-04-2025)
- CDSCO issues Cardio, Neuro device revised classification draft (02-04-2025)
- Gujarat FDCA buys 25 advanced handheld spectrophotometers (02-04-2025)
- Investigation Into Spurious Medicines Ongoing, Court Hearing in May: Tripura CM (02-04-2025)
- WHO issues its first-ever reports on tests and treatments for invasive fungal diseases (01-04-2025)